India is preparing to strengthen its pharmaceutical safety regulations through proposed changes that could make action against substandard medicines faster. The Union Health Ministry has proposed amendments to the Drugs Rules, 1945, allowing authorities to immediately suspend manufacturing licences when medicines fail specified critical quality tests.
The proposal aims to prevent medicines that do not meet prescribed safety and quality standards from remaining in circulation while regulatory procedures are underway.
What Are the Proposed Changes?
Under the proposed amendments, drug manufacturing licences could be suspended immediately if government testing identifies serious quality failures involving:
- Impurities and related substances.
- Sterility requirements.
- Active ingredient content, also known as assay.
- Dissolution standards, which measure how a medicine releases its active ingredient.
The proposed framework seeks to remove delays associated with the existing procedure, which generally involves issuing a show-cause notice before taking suspension or cancellation action.
Why Is the Government Taking This Step?
Medicine quality is an important public health concern. Drugs that fail essential quality standards may not deliver the expected treatment and can create risks for patients.
The Health Ministry has highlighted that delays in regulatory action can allow medicines declared Not of Standard Quality (NSQ) to remain available in the market.
The proposed changes are intended to strengthen monitoring and enable quicker action against manufacturers responsible for serious quality failures.
When Can a Suspended Licence Be Restored?
Under the proposed framework, manufacturers would need to investigate the reasons behind the quality failure and introduce appropriate corrective and preventive measures.
Regulatory authorities would verify whether the required improvements have been implemented before considering the restoration of a suspended licence.
The proposal also seeks to improve communication between government laboratories, central drug regulators and state licensing authorities.
Public Feedback Before Final Implementation
The proposed amendments were published for public consultation, with a 30-day period provided for stakeholders to submit their objections and suggestions.
The changes will become effective only after the final amendments are officially notified.
If implemented, the new framework could strengthen India’s pharmaceutical quality-control system and improve safeguards for patients purchasing medicines across the country.
